Alessandro Larcher1, Umberto Capitanio2, Carlo Terrone3, Alessandro Volpe3, Paolo De Angelis3, Federico Dehó1, Nicola Fossati1, Paolo Dell'Oglio1, Alessandro Antonelli4, Maria Furlan4, Claudio Simeone4, Sergio Serni5, Marco Carini5, Andrea Minervini5, Cristian Fiori6, Francesco Porpiglia6, Alberto Briganti1, Francesco Montorsi1, Roberto Bertini1. 1. Urological Research Institute, Division of Experimental Oncology, Istituto di Ricovero e Cura a Carattere Scientifico and Unit of Urology, Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, Italy. 2. Urological Research Institute, Division of Experimental Oncology, Istituto di Ricovero e Cura a Carattere Scientifico and Unit of Urology, Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, Italy. Electronic address: umbertocapitanio@gmail.com. 3. Department of Urology, University of Piemonte Orientale, Novara, Italy. 4. Department of Urology, Università degli studi e Spedali Civili di Brescia, Brescia, Italy. 5. Department of Urology, Clinica Urologica I, Azienda Ospedaliera Universitaria Careggi, Università degli studi di Firenze, Firenze, Italy. 6. Department of Urology, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Università degli studi di Torino, Orbassano, Italy.
Abstract
PURPOSE: There is no consensus regarding a protective effect on mortality due to a cause other than cancer in patients treated with elective nephron sparing surgery relative to their radical nephrectomy counterparts. We test whether the protective effect of nephron sparing surgery relative to radical nephrectomy is universal or present in specific subgroups of patients. MATERIALS AND METHODS: A collaborative database of 5 institutions was queried to evaluate 1,783 patients without chronic kidney disease diagnosed with a clinical T1 renal mass that was treated with nephron sparing surgery or radical nephrectomy. Multivariable Cox regression analysis was done to assess the impact of surgery type (nephron sparing surgery vs radical nephrectomy) on other cause mortality after adjustment for patient and cancer characteristics. Interaction terms were used to test the hypothesis that the impact of surgery type varies according to specific subcohorts of patients. RESULTS: Ten-year other cause mortality-free survival rates were 90% and 88% after nephron sparing surgery and radical nephrectomy, respectively. In the overall population radical nephrectomy was not associated with an increased risk of other cause mortality on multivariable analysis compared to nephron sparing surgery (HR 0.91, 95% CI 0.6-1.38, p = 0.6). However, radical nephrectomy increased the risk of other cause mortality according to the increasing baseline Charlson comorbidity index (interaction test p = 0.0008). For example, in a patient with a Charlson comorbidity index of 4 the probability of 10-year other cause mortality-free survival was 86% after nephron sparing surgery and 60% after radical nephrectomy. CONCLUSIONS: Elective nephron sparing surgery does not improve other cause survival relative to radical nephrectomy consistently in all patients with kidney cancer. Patients who are more ill with relevant comorbidities are those who benefit the most from nephron sparing surgery in terms of other cause mortality.
PURPOSE: There is no consensus regarding a protective effect on mortality due to a cause other than cancer in patients treated with elective nephron sparing surgery relative to their radical nephrectomy counterparts. We test whether the protective effect of nephron sparing surgery relative to radical nephrectomy is universal or present in specific subgroups of patients. MATERIALS AND METHODS: A collaborative database of 5 institutions was queried to evaluate 1,783 patients without chronic kidney disease diagnosed with a clinical T1 renal mass that was treated with nephron sparing surgery or radical nephrectomy. Multivariable Cox regression analysis was done to assess the impact of surgery type (nephron sparing surgery vs radical nephrectomy) on other cause mortality after adjustment for patient and cancer characteristics. Interaction terms were used to test the hypothesis that the impact of surgery type varies according to specific subcohorts of patients. RESULTS: Ten-year other cause mortality-free survival rates were 90% and 88% after nephron sparing surgery and radical nephrectomy, respectively. In the overall population radical nephrectomy was not associated with an increased risk of other cause mortality on multivariable analysis compared to nephron sparing surgery (HR 0.91, 95% CI 0.6-1.38, p = 0.6). However, radical nephrectomy increased the risk of other cause mortality according to the increasing baseline Charlson comorbidity index (interaction test p = 0.0008). For example, in a patient with a Charlson comorbidity index of 4 the probability of 10-year other cause mortality-free survival was 86% after nephron sparing surgery and 60% after radical nephrectomy. CONCLUSIONS: Elective nephron sparing surgery does not improve other cause survival relative to radical nephrectomy consistently in all patients with kidney cancer. Patients who are more ill with relevant comorbidities are those who benefit the most from nephron sparing surgery in terms of other cause mortality.
Authors: Fabio Crocerossa; Cristian Fiori; Umberto Capitanio; Andrea Minervini; Umberto Carbonara; Savio D Pandolfo; Davide Loizzo; Daniel D Eun; Alessandro Larcher; Andrea Mari; Antonio Andrea Grosso; Fabrizio Di Maida; Lance J Hampton; Francesco Cantiello; Rocco Damiano; Francesco Porpiglia; Riccardo Autorino Journal: Eur Urol Open Sci Date: 2022-03-03